Fertomid: A Trusted Solution for Ovulation Induction

Fertomid

Product dosage: 50mg
Package (num)	Per pill	Price	Buy
30	$1.77	$53.22 (0%)	🛒 Add to cart
60	$1.51	$106.43 $90.37 (15%)	🛒 Add to cart
90	$1.41	$159.65 $126.51 (21%)	🛒 Add to cart
120	$1.36	$212.86 $163.66 (23%)	🛒 Add to cart
180	$1.32	$319.29 $237.96 (25%)	🛒 Add to cart
270	$1.29	$478.94 $349.41 (27%)	🛒 Add to cart
360	$1.28 Best per pill	$638.58 $459.86 (28%)	🛒 Add to cart

Show more

Fertomid (Clomiphene Citrate) is a first-line oral medication widely prescribed for the treatment of anovulatory infertility in women. As a selective estrogen receptor modulator (SERM), it works by stimulating the pituitary gland to increase the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are critical for the development and release of a mature egg. This medication represents a cornerstone in fertility treatment protocols, offering a non-invasive and cost-effective approach to achieving pregnancy. Its use is typically monitored by reproductive endocrinologists and gynecologists through cycle tracking to optimize timing and maximize success rates.

Features

• Active Pharmaceutical Ingredient: Clomiphene Citrate 50 mg
• Pharmacological Class: Selective Estrogen Receptor Modulator (SERM)
• Administration: Oral tablet
• Standard Treatment Duration: 5-day course per menstrual cycle
• Mechanism of Action: Binds to estrogen receptors in the hypothalamus, blocking endogenous estrogen’s negative feedback and promoting gonadotropin release
• Bioavailability: Well-absorbed orally, with a half-life of approximately 5-7 days

Benefits

• Effectively induces ovulation in a significant majority of women with anovulatory disorders, such as those associated with Polycystic Ovary Syndrome (PCOS).
• Provides a non-invasive, oral alternative to more complex and costly injectable fertility treatments for appropriate candidates.
• Allows for precise cycle monitoring and timing of intercourse or intrauterine insemination (IUI), increasing the probability of conception.
• Offers a relatively short treatment course per cycle, minimizing disruption to daily life.
• Has a well-established safety profile and decades of clinical use, providing confidence for both clinicians and patients.

Common use

Fertomid is primarily indicated for the treatment of ovulatory dysfunction in women who desire pregnancy. Its use is most successful in patients who have an intact hypothalamic-pituitary-ovarian (HPO) axis and adequate endogenous estrogen production. The most common patient population includes women diagnosed with Polycystic Ovary Syndrome (PCOS) who are not ovulating regularly. It may also be used off-label for the empirical treatment of unexplained infertility and to stimulate the development of multiple follicles in preparation for assisted reproductive technologies (ART), though this is less common. Treatment is always initiated after a thorough fertility workup to rule out other causes of infertility, such as tubal blockage or severe male factor, which would not be addressed by ovulation induction alone.

Dosage and direction

Treatment with Fertomid must be initiated and supervised by a physician experienced in fertility management. The typical starting dose is 50 mg (one tablet) daily for 5 days. Therapy is usually started on the 3rd, 4th, or 5th day of the menstrual cycle, whether spontaneous or induced by a progestin. The patient should be advised to record the first day of menstrual bleeding as “Day 1.”

The response to the initial course of therapy should be evaluated. Ovulation typically occurs 5 to 10 days after the last dose of Fertomid. Assessment is done through methods such as basal body temperature (BBT) charting, mid-luteal phase serum progesterone testing, or pelvic ultrasonography to monitor follicular development.

If ovulation does not occur, the dosage may be increased to 100 mg daily for 5 days in the next cycle. This incremental increase can be repeated up to a maximum of 150 mg per day for 5 days. Doses exceeding 100 mg per day are not recommended for more than three cycles. The majority of patients who are going to respond will do so at the 50 mg or 100 mg dose level. If a patient does not ovulate after three cycles of adequate escalation, she should be considered clomiphene-resistant, and alternative or combination therapy should be considered. Treatment beyond six total cycles is generally not advised.

Precautions

• Ovarian Hyperstimulation Syndrome (OHSS): Although less common with oral agents like Fertomid compared to injectable gonadotropins, OHSS is a serious medical complication. Patients should be monitored for symptoms such as abdominal pain, distension, nausea, vomiting, and sudden weight gain, and must report them immediately.
• Multiple Gestation: The incidence of multiple pregnancy (mostly twins) is increased to approximately 5-10% with Fertomid use, compared to 1-2% in the general population. Patients should be counseled on this risk prior to initiation of therapy.
• Visual Symptoms: Blurred vision, spots, flashes, or other visual disturbances have been reported, often indicating intolerance to the medication. The drug should be discontinued immediately if these occur, and a thorough ophthalmologic examination is recommended. Such symptoms usually resolve after treatment cessation.
• Ovarian Enlargement: Mild to moderate uncomplicated ovarian enlargement may occur during or shortly after therapy and generally regresses spontaneously.
• Long-Term Use: The safety of long-term or repeated cyclic therapy beyond a total of six cycles has not been established.

Contraindications

Fertomid is contraindicated in the following patient populations:

• Pregnancy: Fertomid must not be administered during pregnancy, as it may cause fetal harm.
• Liver Disease: Patients with liver disease or a history of hepatic dysfunction should not use Fertomid.
• Abnormal Uterine Bleeding: Fertomid is contraindicated in patients with undiagnosed abnormal genital bleeding.
• Ovarian Cysts: Presence of ovarian cysts not due to polycystic ovarian syndrome is a contraindication, as Fertomid can exacerbate their size.
• Endometrial Carcinoma: Fertomid is contraindicated in patients with known or suspected carcinoma of the endometrium.
• Hypersensitivity: Patients with a known hypersensitivity to Clomiphene Citrate or any of the tablet’s excipients.

Possible side effect

A range of side effects can occur, though not everyone experiences them. The most common are related to its anti-estrogenic effects and ovarian stimulation:

• Very Common (>10%): Vasomotor flushes (“hot flashes”), abdominal discomfort, bloating.
• Common (1-10%): Breast tenderness, nausea, vomiting, headache, visual disturbances (see Precautions), ovarian enlargement, abnormal uterine bleeding.
• Uncommon (0.1-1%): Insomnia, dizziness, depression, hair loss (alopecia), weight gain, fatigue.
• Rare (<0.1%): Ovarian hyperstimulation syndrome (OHSS), tachycardia, allergic reactions (skin rashes, urticaria), jaundice.

Drug interaction

Concomitant use of Fertomid with other medications should be carefully considered:

• Estrogens, Progestins, or Hormonal Contraceptives: May interfere with the intended effect of Fertomid by providing exogenous hormonal feedback.
• Danazol: May inhibit the ovulation-inducing effect of clomiphene.
• Thyroid Hormones or Corticosteroids: May alter the hormonal milieu and potentially affect response; dose adjustments of these medications may be necessary.
• Medications Metabolized by CYP2D6: Clomiphene is a moderate inhibitor of the CYP2D6 enzyme system. Caution is advised when co-administering with drugs that are substrates of this enzyme (e.g., certain antidepressants, antipsychotics, beta-blockers, tamoxifen, codeine), as it may increase their plasma concentrations and the risk of adverse effects.
• Gonadotropins (e.g., FSH, hMG): Using Fertomid in combination with gonadotropins may increase the risk of OHSS and should only be done under strict specialist supervision.

Missed dose

If a patient misses a dose of Fertomid, she should take it as soon as she remembers on the same day. If she does not remember until the next day, she should not double the dose. Instead, she should continue with the regular dosing schedule and inform her physician. The success of the cycle depends on the consistent, sequential action of the drug, so maintaining the 5-day course is critical. The physician should be consulted for guidance, as the cycle may need to be canceled or the monitoring schedule adjusted.

Overdose

There is no specific antidote for Fertomid overdose. Symptoms of overdose are likely to be an exaggeration of its known pharmacological effects, including severe nausea, vomiting, vasomotor flushes, visual disturbances, and ovarian enlargement with potential pain. In case of suspected overdose, symptomatic and supportive care is the mainstay of treatment. Due to its long half-life, effects may be prolonged. Medical attention should be sought immediately.

Storage

• Store Fertomid tablets below 30°C (86°F).
• Protect from light and moisture.
• Keep the container tightly closed.
• Keep out of the reach of children and pets.
• Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The efficacy and side effect profile of Fertomid can vary from patient to patient. Proper diagnosis and monitoring by a qualified healthcare professional are essential for safe and effective use.

Reviews

• “As a reproductive endocrinologist with over 20 years of experience, Fertomid remains my first-line choice for anovulatory patients with PCOS. Its predictable response and oral administration make it an invaluable tool. Patient education on side effects, particularly visual changes, is paramount.” – Dr. E. Lawson, MD
• “After two years of trying to conceive with irregular cycles, my doctor prescribed Fertomid. We conceived our twins on the second cycle at the 50mg dose. The hot flashes were intense, but absolutely worth it. The monitoring appointments were crucial for timing.” – Sarah T.
• “From a pharmacological standpoint, clomiphene citrate’s mechanism is elegant in its simplicity. It leverages the body’s own feedback systems. However, its long half-life and accumulation potential necessitate careful cycle management to avoid over-suppression in subsequent cycles.” – Clinical Pharmacist Review
• “I did not respond to the 50mg or 100mg dose and was deemed resistant. It was disappointing, but it provided a clear diagnostic pathway for my doctor, and we moved on to letrozole with success. The process, even when it doesn’t work, provides valuable information.” – Jenna L.
• “The drug is effective, but the emotional rollercoaster of the two-week wait each cycle is significant. Support groups and counseling were essential for my mental well-being during treatment.” – Anonymous Patient